Two series of carbazole analogs of 8-methoxy-N-substituted-9H-carbazole-3-carboxamides (series 1) and carbazolyl substituted rhodanines (series 2) were synthesized through facile synthetic routes. All the final compounds from these two series were evaluated for their preliminary in vitro antifungal and antibacterial activity against four fungal (Candida albicans, Cryptococcus neoformans, Cryptococcus tropicalis and Aspergillus niger) and four bacterial (Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa) strains, respectively. Among the tested compounds, three compounds of series 1 displayed promising antifungal and antibacterial activity, especially against C. neoformans and S. aureus. In addition, one compound of series 1 displayed notable antimicrobial activity (MIC: 6.25 μg/mL) against clinical isolates of C. albicans and C. neoformans (MIC: 12.5 μg/mL). From the second series, four compounds exhibited significant antifungal and antibacterial activity, especially against C. neoformans and S. aureus. The most active compound of series 2 displayed a prominent antimicrobial activity against C. neoformans (MIC: 3.125 μg/mL) and S. aureus (MIC: 1.56 μg/mL), respectively.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbdv.201900550DOI Listing

Publication Analysis

Top Keywords

antifungal antibacterial
12
antibacterial activity
12
series displayed
12
activity neoformans
12
series
8
compounds series
8
neoformans aureus
8
compound series
8
antimicrobial activity
8
neoformans mic
8

Similar Publications

Berberine enhances the antibacterial activity of thymoquinone, carvacrol and thymol against multi-drug resistant nontuberculous mycobacteria.

Pol J Vet Sci

September 2024

Department of Biology and Fish Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland.

The aim of this study was to investigate the activity of thymoquinone (TQ), carvacrol (CAR) and thymol (TYM) against multi-drug resistant nontuberculous mycobacteria (MDR-NTM), alone and in combination with berberine (BER). Antimicrobial activity was first evaluated at concentrations from 8 to 512 μg/mL. Each of the compounds tested exhibited good activity against nontuberculous mycobacteria (NTM) isolated from fish, with MIC values of 32-128 μg/mL.

View Article and Find Full Text PDF

Background: Actinobacteria are major producers of antibacterial and antifungal metabolites and are growing their search for substances of biotechnological interest, especially for use in agriculture, among other applications. The Amazon is potentially rich in actinobacteria; however, almost no research studies exist. Thus, we present a study of the occurrence and antifungal potential of actinobacteria from the rhizosphere of , a native South American plant and one that is economically useful in the whole of the Amazon.

View Article and Find Full Text PDF

Antibacterial potential and phytochemical analysis of two ethnomedicinally important plants.

Curr Res Microb Sci

November 2024

Microbiology and Plant Pathology Laboratory, Department of Botany, Jai Narain Vyas University, Jodhpur, Rajasthan, India.

Medicinal plants exhibited great role in drug industries. Herbal medicines and their derivative products are often prepared from crude plant extracts. and both are belonging to Asteraceae family and these plants are ethnomedicinally important due to their utilization as traditional medicine to cure various diseases.

View Article and Find Full Text PDF

Emerging multidrug-resistant (MDR) strains are the main challenges to the progression of new drug discovery. To diminish infectious disease-causing pathogens, new antibiotics are required while the drying pipeline of potent antibiotics is adding to the severity. Plant secondary metabolites or phytochemicals including alkaloids, phenols, flavonoids, and terpenes have successfully demonstrated their inhibitory potential against the drug-resistant pathogens.

View Article and Find Full Text PDF

Introduction: Obesity constitutes a global public health problem, and knowledge about drug dosing in obese patients is limited. Clinical trials in critically ill patients rarely include obese individuals, resulting in a lack of specific dosing information in product data sheets. The aim of this literature review is to provide clinicians with efficient and safe guidelines for this group of patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!